Business Wire

ADVA

Share
Equinix connects Antoni van Leeuwenhoek hospital with ADVA’s encrypted transport solution

ADVA (FSE: ADV) today announced that Equinix – the world’s digital infrastructure company – has deployed ADVA’s FSP 3000 open optical transport technology to provide Antoni van Leeuwenhoek, one of the Netherland’s leading hospitals, with encrypted dark fiber and fully managed services. Linking the healthcare provider’s data centers and facilities, the solution enables Equinix Managed Services to deliver secure Ethernet services up to 40GbE and highly reliable, low-latency Fibre Channel storage area network (SAN) connectivity up to 32Gbit/s. With ADVA’s ConnectGuard optical encryption technology ensuring robust data protection, the solution gives the hospital access to bandwidth-hungry applications and allows patient and medical research information to be securely collected, managed, analyzed and shared.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005540/en/

“By harnessing ADVA FSP 3000 technology and the support of the ADVA and TrueCom teams, we’re enabling Antoni van Leeuwenhoek hospital to transform its operations. With high-capacity, low-latency connectivity to its data centers, all protected by robust encryption at the optical layer, the hospital’s medics and support staff can leverage new applications and collaborate like never before to advance cutting-edge research and enhance patient care,” said Art de Blaauw, director of technology and innovation, Managed Services Solutions at Equinix. “It’s crucial for the healthcare industry that patient data is secure. ADVA’s ConnectGuard solution safeguards the network stack without adding latency or affecting throughput. That means medical practitioners can access critical information at any time, which is crucial for efficient processes and patient outcomes.”

Built on ADVA’s FSP 3000 open optical transport solution, the new network is capable of secure high-capacity transmission of Ethernet services up to 40GbE. With its agile, scalable and modular design, the FSP 3000 provides a truly flexible foundation, ready to expand and evolve as the needs of the healthcare provider change. The solution enables a high-speed SAN capable of transporting 32Gbit/s Fibre Channel, ensuring rapid access to patient information. This is key for healthcare professionals dealing with huge data sets. The infrastructure is comprehensively secured at the physical layer by ADVA FSP 3000 ConnectGuard™ , which is easy to operate and highly efficient, delivering the lowest cost per bit of any network encryption solution available today. ADVA’s partner TrueCom also played a key role in this project, providing installation and support, ensuring the new infrastructure met all the end customer’s requirements.

“We’re proud that our solution is now helping another major healthcare provider optimize its operations. Protecting the integrity and privacy of patients’ sensitive data couldn’t be more critical. That’s why our security technology is so important here. It ensures valuable data remains safe at every stage of its journey, while data-intensive applications continue to run,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “Approved by the German Federal Office for Information Security (BSI), our FSP 3000 ConnectGuard optical encryption ensures that patient records are protected by the most robust security methods available while adding virtually no delay.”

“There’s no doubt that the medical industry is at the forefront of the battle against cybercrime. Criminals see healthcare providers as treasure troves of valuable data that can easily be monetized. But thanks to our close collaboration with Equinix and ADVA, this hospital can be assured that its systems are secured,” said Dhieradj Ramanand, optical solutions sales manager at TrueCom. “With the ADVA FSP 3000 ConnectGuard optical security solution safeguarding data in motion right across the network, encrypted signals become worthless to a hacker. That’s why this technology is the last word in data security. It’s also the key to peace of mind for medical practitioners and their patients.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse and Hungary Establish Landmark Nuclear Fuel Partnership8.11.2025 15:00:00 CET | Press release

First Contract Signed with MVM Group to Deliver VVER-440 Fuel to Paks Nuclear Power Plant Westinghouse Electric Company and MVM Group signed a contract to ensure diversification of fuel supply in Hungary. This partnership brings to Paks Nuclear Power Plant (NPP) reliable supply with Westinghouse VVER fuel, manufactured in Europe. The Westinghouse VVER-440 fuel reload deliveries will start in 2028, subject to licensing activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107682814/en/ Westinghouse Nuclear Fuel Senior Vice President Aziz Dag, left, and Károly Mátrai, CEO of the MVM Group, signed the Paks VVER-440 contract, Nov. 7, 2025. “Our agreement with Westinghouse is a clear response to today's energy challenges and further strengthens the role of Hungary's leading base power plant in the domestic energy supply. This strategically important step will make the operation of Paks Nuclear Power Plant safer and more f

OMRON Releases the “Medium-Term Roadmap SF 2nd Stage”8.11.2025 07:00:00 CET | Press release

OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November 7, 2025 (JST). This Roadmap presents the Group’s vision and growth strategies through 2030, which are disclosed on our corporate website. Overview of the “Medium-Term Roadmap SF 2nd Stage” Since April 2024, OMRON has been implementing a Structural Reform Program “NEXT 2025” aimed at rebuilding our foundation for profitability and growth. With the completion of this Program in September 2025, we have shifted into a growth phase and formulated a new Roadmap looking ahead to 2030. This Roadmap identifies Business Portfolio Restructuring as a core strategy. We have defined Thirteen Focus Businesses to drive the Group’s future growth. By accelerating our selection and concentration efforts, we aim to build a “distinctive” business portfolio that maximizes overall Group growth. Furthermore, to maximize the growth potential of our Focus Busines

26th UN Tourism General Assembly kicks off in Riyadh7.11.2025 22:13:00 CET | Press release

UN Tourism marks 50 years of global cooperation as leaders from across the industry gather to shape the future of tourism. His Excellency Ahmed Al Khateeb, Minister of Tourism – “The Kingdom will play an integral part in ensuring one of the world’s most powerful generators of jobs and GDP grows in harmony with the Sustainable Development Goals.” UN Tourism Secretary-General ZurabPololikashvili – “The UN Tourism General Assembly brings together tourism leaders from across the world to set the agenda and build a more innovative and inclusive sector. From Riyadh, we will set the agenda for tourism for the years ahead.” The 26th session of the UN Tourism General Assembly opened today in Riyadh, marking a historic first for the Gulf Cooperation Council (GCC) region and the largest Assembly since UN Tourism was founded 50 years ago. Around 160 delegations from member states including ministers, senior officials, and leaders from across industry and civil society are coming together to celebr

Xsolla Partners With Deloitte Turkiye and Lorien Accelerator as Category Sponsor for Gaming Awards at Fast 50 Türkiye 2025 Program7.11.2025 19:11:00 CET | Press release

Celebrating Turkey’s Gaming Industry with High-Impact Sponsorship and Industry Panel Xsolla, a leading global video game commerce company that helps developers launch, grow, and monetize their games, is proud to announce its sponsorship of the Gaming Awards segment at the Deloitte Technology Fast 50 Türkiye 2025 Program, organized in collaboration with Lorien Accelerator. The event will take place on December 10, 2025, and will recognize Turkey’s top high-growth companies across various industries, with a special focus on the dynamic gaming sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107671030/en/ Graphic: Xsolla As the Gaming Awards category sponsor, Xsolla will receive significant brand exposure through prominent logo placements across all event materials, including digital platforms, official event signage, and other promotional materials. In addition to this visibility, Xsolla’s participation includes an ex

Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy7.11.2025 17:00:00 CET | Press release

− Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 Months After Last Dose1− Rapid Reductions in Proteinuria and Serum Gd-IgA1 Levels Were Sustained Through Week 961− No Serious Adverse Events or Opportunistic Infections Were Observed Through Week 961− Takeda Initiated Pivotal Phase 3 Clinical Trials Evaluating Mezagitamab in Primary IgA Nephropathy and Immune Thrombocytopenia with Patient Enrollment Ongoing Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The results were presented at the American Society o

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye